The Association of Corporate Counsel (ACC) Greater Philadelphia and JAMS Present Top 5 Cross-Border Life Sciences Intellectual Property Licensing Risks: How ADR Can Help Resolve Them

Cross-border collaborations in the life sciences—spanning pharmaceuticals, medical devices, diagnostics, and digital health—depend on complex IP licensing arrangements. Even well-drafted agreements, however, can be destabilized by differing legal regimes, discovery standards, procedural norms, and enforcement mechanisms across jurisdictions. These challenges create material legal and business risk that can threaten innovation, timelines, and commercial value.

This CLE program examines five recurring risks that arise in cross-border life sciences IP licensing and explores how alternative dispute resolution (ADR), including mediation and arbitration, can help manage and mitigate those risks. Participants will gain practical insight into structuring dispute resolution mechanisms that promote efficiency, neutrality, confidentiality, and enforceability, while aligning legal strategy with business objectives in a global regulatory environment.